Anti-CA19-9/CEA chimeric antigen receptor T cell therapy (SMT Bio/Yonsei Medical Center)

N/A

Report date: 2024/06/04 16:17:35

Base Information

Drug NameAnti-CA19-9/CEA chimeric antigen receptor T cell therapy (SMT Bio/Yonsei Medical Center)
Drug Alias NameAnti-CA19-9/carcinoembryonic antigen chimeric antigen receptor T cell therapyAnti-CA19-9/CEA CAR T cell therapyAnti-CEA/CA19-9 CAR T cell therapyAnti-CEA/CA19-9 chimeric antigen receptor T cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CA19.9(Carbohydrate antigen 19-9) +[4] 
TargetsCA19.9(Carbohydrate antigen 19-9)Carcinoembryonic antigen
Therapy Area/IndicationsPancreatic NeoplasmsBiliary Tract Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesYonsei UniversitySmt Bio
China Registration ClassN/A

Develop Information

Active CompaniesSmt BioYonsei University
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsBiliary Tract Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A